Glial Cell Line-Derived Neurotrophic Factor - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.

27 Jul 2009 Neurotrophic factors are promising candidates for the treatment of Parkinson's disease (PD). Mesencephalic astrocyte-derived neurotrophic factor (MANF) belongs to a novel evolutionarily conserved family of neurotrophic factors. We examined whether ... Read more...

Local delivery of glial cell line-derived neurotrophic factor improves facial nerve regeneration after late repair.

29 Apr 2009 OBJECTIVES/HYPOTHESIS: Facial nerve regeneration is limited in some clinical situations: in long grafts, by aged patients, and when the delay between nerve lesion and repair is prolonged. This deficient regeneration is due to the limited number of ... Read more...

Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor.

30 Jan 2009 We previously found that activation of the glial cell line-derived neurotrophic factor (GDNF) pathway in the ventral tegmental area (VTA) reduces moderate alcohol (ethanol) intake in a rat operant self-administration paradigm. Here, we set out to ... Read more...

Latest indexed articles for 'Glial Cell Line-Derived Neurotrophic Factor - Administration & dosage'

These are the very latest articles for this heading:

• Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. 27 Jul 2009
• Local delivery of glial cell line-derived neurotrophic factor improves facial nerve regeneration after late repair. 29 Apr 2009
• Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. 30 Jan 2009
• Controlled release of GDNF reduces nerve root-mediated behavioral hypersensitivity. 30 Dec 2008
• Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. 23 Dec 2008
• Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. 21 Dec 2008
• [Gene therapy for ischemic stroke] 30 Oct 2008
• Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. 4 Sep 2008
• Calbindin-D28K expression induced by glial cell line-derived neurotrophic factor in substantia nigra neurons dependent on PI3K/Akt/NF-kappaB signaling pathway. 28 Jul 2008
• GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. 30 May 2008
• Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys. 29 Mar 2008
• Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. 28 Feb 2008
• Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. 21 Feb 2008
• Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys. 30 Dec 2007
• Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. 22 Sep 2007
• Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? 12 Sep 2007
• Variations in glial cell line-derived neurotrophic factor release from biodegradable nerve conduits modify the rate of functional motor recovery after rat primary nerve repairs. 30 Aug 2007
• Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. 12 Jul 2007
• Second chance. 27 Jun 2007
• Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. 19 May 2007

See a longer list of these articles.

Technical information about 'Glial Cell Line-Derived Neurotrophic Factor'

Definition: The founding member of the glial cell line-derived neurotrophic factor family. It was originally characterized as a NERVE GROWTH FACTOR promoting the survival of MIDBRAIN dopaminergic NEURONS, and it has been studied as a potential treatment for PARKINSON DISEASE.

Registry Number: 0

Descriptor UI: D051100

Alternative terms: Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line Derived Neurotrophic Factor; GDNF Growth Factor; Growth Factor, GDNF; Glial Cell-Line Derived Neurotrophic Factor; GDNF;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.860.381.500; D12.776.467.860.381.500; D12.776.641.600.381.500; D23.529.850.381.500;

History Note: 2006(1993)

Technical Notes: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS is also available